PFE - Pfizer Inc
A pharmaceutical heavyweight known for COVID-19 vaccines and treatments, now working to rebuild growth momentum through oncology acquisitions and pipeline diversification.
Finlify Score
51.2 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$27.72
+0.25%
52W Range
$23.58 - $29.21
Market Cap
$162.2B
+0.3%Compared to previous day
2026 Q1 Revenue
$12.1B
+133.1%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
45.4
40-70 moderate
2Y Range Position
72%
-8.9% from high / +32.5% from low
Beta
0.28
Relative to market benchmark
MACD
-0.18
MACD line 0.46 / signal line 0.64
Fundamental Trend
Growth 58.2Financial Health
Quality 85.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD51.2 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $12.1B+133.1% | -$36.5B-354.5% | $14.4B+16.0% | $12.4B+6.7% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $2.7B+263.0% | -$1.6B-146.5% | $3.5B+21.7% | $2.9B-1.9% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for PFE is currently a HOLD, with an overall Finlify Score of 51.7 out of 100. This stance appears to be influenced by strong fundamental and financial quality scores, balanced against weaker technical indicators and partial data quality.
Technical
The asset's Relative Strength score is relatively low at 18.5/100, suggesting some recent underperformance compared to its peers. While the 20-day return shows a positive 4.3%, the 60-day return indicates a decline of -5.3%. The Accumulation / Volume score of 41.8/100 suggests moderate buying interest, and the RSI(14) at 50.9 indicates a neutral momentum stance.
Fundamentals
PFE exhibits strong fundamental characteristics, with a Fundamental Trend score of 73.8/100 and an impressive Financial Quality score of 85.8/100. Its valuation metrics include a P/E ratio of 18.4x, P/B of 1.6x, and P/S of 2.3x. The asset also offers a notable Dividend Yield of 6.90% and appears to have lower volatility with a Beta of 0.3.
Macro Context
In an environment with CPI YoY at 3.7% and Core PCE YoY at 3.3%, PFE's substantial dividend yield of 6.90% may offer an attractive income stream, potentially appealing to investors seeking defensive assets amid moderate inflation and a 10Y Treasury Yield of 4.7%. The positive yield spread of 0.5% could also suggest a more stable economic outlook, which may generally support pharmaceutical companies.
Key Risks
- The 'PARTIAL' data quality, including the use of an EPS proxy and a -1.0 deduction, may introduce some uncertainty into the signal's comprehensiveness.
- The relatively low Relative Strength score of 18.5/100 and a negative 60-day return of -5.3% suggest potential recent underperformance.
- Upcoming earnings on 2026-08-04 could introduce significant price volatility for the asset.